Loading stock data…
NVCR
$17.24+0.39 (+2.31%)
After Hours$17.24+0.00 (+0.00%)· Last close Jun 9
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovoCure Limited in the Healthcare sector is trading at $17.24 with a market capitalization of $1.9B. Wall Street consensus targets $26.29 (7 analysts), implying a +52.5% move over the next 12 months. The stock is currently 10% below its 52-week high of $19.25, remaining 30.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +52.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$17.24
Potential Downside
0%
Whystock Fair Value$17.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$26.29+52.5%
Range$17.00 – $48.00
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.32%
Volume
Today's trading volume
1.38M
Recent News
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing
This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)
At NovoCure’s annual general meeting held on June 3, 2026, shareholders elected Frank Leonard to the board as a director through the 2027 meeting, marking a change in the company’s governance lineup. This board addition comes as NovoCure faces questions around recent insider share sales and an assessment that the stock may be trading below its estimated intrinsic value. We’ll now examine how Frank Leonard’s appointment to the board, alongside concerns over insider selling, may influence...
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
3 Overlooked Stocks Set to Soar in 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.